Ho D W Y, Fan S T, To J, Woo Y H, Zhang Z, Lau C, Wong J
Centre for the Study of Liver Disease and Department of Surgery, University of Hong Kong, Hong Kong.
Gut. 2002 Jun;50(6):869-76. doi: 10.1136/gut.50.6.869.
Plasma exchange may be useful for treating patients with fulminant hepatic failure but during the procedure growth factors that are important for hepatic regeneration are discarded. Addition of a selective plasma filter to the plasmapheresis circuit could eliminate protein bound toxic substances and retain growth factors for hepatic regeneration. This process is called selective plasma filtration.
To determine if selective plasma filtration could be a useful treatment modality for fulminant hepatic failure.
The system was tested in five groups of pigs with fulminant hepatic failure induced by galactosamine: group I, diseased control group (n=5); group II, sham control, (n=6); group III, plasma exchange (n=6); group IV, treatment with AC-1770 selective plasma filter (n=7); and group V, treatment with AC-1730 selective plasma filter which had a smaller pore size than AC-1770 (n=7). Fresh pig plasma was given to replace filtered plasma in pigs of groups III, IV, and V. Treatment was initiated 48 hours after administration of 0.75 g/kg galactosamine. The efficacy of selective plasma filtration was assessed by survival rate and improvement in haematological, biochemical, and immunohistological parameters.
Pigs treated with AC-1770 or AC-1730 selective plasma filters survived longer than the other groups (group I: 55 (10) hours; group II: 68 (7) hours; group III: 91 (10) hours; group IV: 269 (156) hours; group V: 950 (555) hours). One pig in group IV survived for 50 days; one pig in group V survived for 77 days and another pig in group V is still alive (>150 days). After treatment, plasma levels of aspartate aminotransferase, bilirubin, bile acid, ammonia, lactate dehydrogenase, and alpha-glutathione-S-transferase decreased. Substantial amounts of tumour necrosis factor alpha (TNF-alpha) and endotoxin were found in the filtrate. The selective plasma filtration groups retained significantly higher amounts of hepatocyte growth factor than plasma exchange alone. Similar TNF-alpha clearance was observed in the selective plasma filtration groups and the plasma exchange group. On day 4, significant improvement in liver function, as measured by the indocyanine green clearance test, was observed in groups IV and V but not in the other groups. A higher regeneration index of hepatocytes was also observed in the groups treated with AC-1770 and AC-1730 selective plasma filters.
Selective plasma filtration improved survival time and expedited liver regeneration in pigs with fulminant hepatic failure.
血浆置换可能有助于治疗暴发性肝衰竭患者,但在此过程中,对肝脏再生很重要的生长因子被丢弃了。在血浆置换回路中添加选择性血浆滤器可以清除与蛋白质结合的有毒物质,并保留用于肝脏再生的生长因子。这个过程称为选择性血浆滤过。
确定选择性血浆滤过是否可能是治疗暴发性肝衰竭的一种有效治疗方式。
该系统在五组由半乳糖胺诱导暴发性肝衰竭的猪身上进行了测试:第一组,患病对照组(n = 5);第二组,假手术对照组(n = 6);第三组,血浆置换组(n = 6);第四组,用AC - 1770选择性血浆滤器治疗组(n = 7);第五组,用孔径比AC - 1770小的AC - 1730选择性血浆滤器治疗组(n = 7)。给第三、四、五组的猪输入新鲜猪血浆以替代滤过的血浆。在给予0.75 g/kg半乳糖胺48小时后开始治疗。通过生存率以及血液学、生化和免疫组织学参数的改善来评估选择性血浆滤过的疗效。
用AC - 1770或AC - 1730选择性血浆滤器治疗的猪比其他组存活时间更长(第一组:55(10)小时;第二组:68(7)小时;第三组:91(10)小时;第四组:269(156)小时;第五组:950(555)小时)。第四组有1头猪存活了50天;第五组有1头猪存活了77天,另一头猪仍存活(>150天)。治疗后,天冬氨酸转氨酶、胆红素、胆汁酸、氨、乳酸脱氢酶和α - 谷胱甘肽 - S - 转移酶的血浆水平下降。在滤液中发现了大量肿瘤坏死因子α(TNF - α)和内毒素。选择性血浆滤过组比单纯血浆置换组保留了显著更多的肝细胞生长因子。在选择性血浆滤过组和血浆置换组中观察到相似的TNF - α清除率。在第4天,通过吲哚菁绿清除试验测量,第四组和第五组的肝功能有显著改善,而其他组没有。在用AC - 1770和AC - 1730选择性血浆滤器治疗的组中也观察到肝细胞的再生指数更高。
选择性血浆滤过改善了暴发性肝衰竭猪的生存时间并加速了肝脏再生。